Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1998-04-29
2000-05-16
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514220, 540460, 540497, 544244, 544250, A61K 31495, C07D48714
Patent
active
060637749
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention pertains to tricyclic quinoxaline derivatives that are neuroprotective agents. In particular, the invention pertains to AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor and glutamate antagonists (NMDA antagonists, i.e., n-methyl-D-aspartate).
BACKGROUND OF THE INVENTION
Over excitation of NMDA receptor channel complexes on postsynaptic neurons following excessive release of glutamic acid from synaptosomes and glutamic acid from synaptosomes and glial cells results in a massive calcium ion influx into the neuronal cells, which leads to their death. This is believed to occur under ischemic or hypoxic conditions such as stroke, hypoglycemic, cardiac arrest and physical trauma. An NMDA receptor antagonist might be therapeutically useful because it may minimize damage of the central nervous system induced by ischemic or hypoxic conditions. The NMDA receptor channel complex consists of at least three binding domains including glutamic acid (or NMDA) recognition site, channel blocking binding site, and strychnine-insensitive glycine binding type. Physiologically, a blockade of at least one of these sites terminates the channel opening of the NMDA receptor to prevent a calcium ion influx J. Med. Chem., 1994;37:3956-3968, R. Nagata, et al.
Excessive excitation by neurotransmitters may be responsible for the loss of neurons in cerebral vascular disorders such as cerebral ischemia or cerebral infarction resulting in a range of conditions such as thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, perinatal, asphyxia anoxia, such as from near drowning, pulmonary surgery, and cerebral trauma, as well as lathyrism, Alzheimer's disease, and Huntington's disease. Such conditions likewise suggest the use of agents that may act as antagonists in the receptors identified above may lead to treatment of Amyotrophic lateral sclerosis (ALS), schizophrenia, Parkinsonism, epilepsy, anxiety, pain, and drug addiction. PCT/EPO 94/01492 having publication number WO94/26747 published Nov. 24, 1994, Watjen, et al.
L-glutamic acid, L-aspartic acid, and a number of other closely related amino acids have the ability to activate neurons in the nervous system. Therefor the vast majority of excitatory neurons in the mammalian CNS. Interaction with glutamic acid mediated neurotransmission is considered a useful approach in the treatment of neurological and psychiatric diseases. WO94/26746, published Nov. 24, 1994, Jacobsen, et al.
Tricyclic quinoxaline diones as glutamate receptor antagonists are described in WO93/08188, published Apr. 29, 1993, R. Magata, et al.
WO92/22552, published Dec. 23, 1992, Tenbrink, et al., discloses imidazolo quinoxaline materials that are useful an anxiolytic and sedative/hypnotic agents.
European Patent Application 627,434, published Dec. 7, 1994, R. Nagata, et al., discloses tricyclic quinoxaline dione derivatives which are selective antagonists of the glycine binding site of the NMDA receptor.
It is an object of the present invention to disclose AMPA/GLY antagonists which are useful as neuroprotective agents.
It is a further object of the present invention to describe novel conformationally constrained tricyclic quinoxaline dione derivatives.
SUMMARY OF THE INVENTION
Described are tricyclic quinoxaline dione compositions of Formula I ##STR2## wherein a is a ring of 6 to 8 members; n or n' independently is an integer of from 1 to 2; sulfur,
Also described are tricyclic quinoxaline dione compositions of Formula I with the further definition that when ring a is a 7- or 8-membered ring, R.sub.7 may also be --N(R.sub.1).sub.2, --SONR.sub.8 R.sub.9, or --NHCOR.sub.8.
Also described is a method for or treatment of neurodegenerative disorders including ALS, stroke such as thromboembolic or hemorrhagic, hypoglycemic conditions, cardiac arrest, trauma, ischemia, cerebral infarction, status epilepticus, perinatal, asphyxia anoxia, Lathyrism, Alzheimer's disease, Huntington's disease, schizophrenia, P
REFERENCES:
patent: 5532236 (1996-07-01), Jacobsen et al.
patent: 5574038 (1996-11-01), Jacobsen
Kukla et al. Synthesis and Anti HiV activity . . . J. Med. Chem. 34, 3187-3197, 1991.
Lipton, S. Prospects for clinically tolerated NMDA antagonists . . . TINS. 16(12), 527-532, 1993.
Lees, G.J. Therapeutic Potential of AMPA Receptor Ligands . . . CNS Drugs 5(1) 51-74, 1996.
Doble, A. Excitatory aminoacid receptors and neurodegeneration. Therapie 50, 319-337, 1995.
PCT International Search Report PCT/US97/23254.
Moon et al., "Dopaminergic and Serotonergic Activities of Imidazoquinolinones and Related Compounds", J. Med. Chem., 1992, 35, pp. 1076-1092.
Nagata et al., "Structure-Activity Relationships of Tricyclic Quinoxalinediones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor 1", Bioorganic & Medicinal Chemisty Letters, 1995, vol. 5, No. 14, pp. 1527-1532.
Nagata et al., "Structure-Activity Relationships of Tricyclic Quinoxalinediones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor 2", Biorganic & Medicinal Chemistry Letters, 1995, vol. 5, No. 14, pp. 1533-1536.
Nagata et al., "Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor", J. Med. Chem., 1994, 37, pp. 3956-3968.
Kornhuber et al. "Psychotogenicity and N-methyl-D-aspartate Receptor Antagonism: Implications for Neuroprotective Pharmacotherapy" Biol Psychiatry (1997) 41, 135-144, 1997.
Anderson Elizabeth M.
Balasubramanian V
Raymond Richard L.
Warner-Lambert & Company
LandOfFree
Tricyclic quinoxaline derivatives as neuroprotective agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic quinoxaline derivatives as neuroprotective agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic quinoxaline derivatives as neuroprotective agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-259029